Loading...
•
Sep 30, 2023
10X Genomics Q3 2023 Earnings Report
Reported a 17% revenue increase driven by Xenium momentum.
Key Takeaways
10x Genomics reported a solid third quarter with revenue reaching $153.6 million, a 17% increase compared to the previous year, driven by strong Xenium performance. The company is raising its full year 2023 revenue guidance to $610 million to $625 million, representing 18% to 21% growth over full year 2022.
Revenue was $153.6 million, a 17% increase year-over-year, driven by Xenium momentum.
Advanced Xenium gene panel strategy by launching new targeted and custom kit configurations.
Expanded the capabilities of the Chromium Single Cell Gene Expression Flex assay.
Announced a partnership with Beckman Coulter Life Sciences to expand automation solutions for single cell assay workflows.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $610 million to $625 million, representing 18% to 21% growth over full year 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...